Anemia is a common issue in patients with myelofibrosis. © relif – stock.adobe.com Anemia is a common and potentially dangerous condition that can occur in patients with myelofibrosis, a type of myeloproliferative neoplasm. While anemia is a blanket term that describes low hemoglobin levels, myelofibrosis-related anemia behaves quite differently than anemia in patients with a […]
Olatoyosi Odenike, MD When treating patients who present with accelerated- or blast-phase myeloproliferative neoplasms (MPN AP or MPN BP), Olatoyosi Odenike, MD, professor of medicine and director, Leukemia Program at the University of Chicago Medicine in Illinois, said the 3 most important considerations are the choice of initial therapy, whether the patient is eligible for […]
Transcript: Sameh R. Gaballa, MD: This is an area where there’s a lot of heterogeneity in terms of practice. What do you do after you’re done with induction? You get an end-of-treatment PET and the patient is in CR [complete response]. How do you monitor these patients? How often do you get imaging? I agree […]
Introduction In the context of an alarming decline in HPV vaccination coverage globally, from 25% to 15% between 2019 and 2021, the WHO recommends that countries reinforce their HPV vaccination programs.1 Also, according to The European Cancer Organization report, it is estimated that about 29% of girls and 5% of boys were completely vaccinated with […]
Abstract Clonal hematopoiesis (CH)—age-related expansion of mutated hematopoietic clones—can differ in frequency and cellular fitness by CH type (e.g., mutations in driver genes (CHIP), gains/losses and copy-neutral loss of chromosomal segments (mCAs), and loss of sex chromosomes). Co-occurring CH raises questions as to their origin, selection, and impact. We integrate sequence and genotype array data […]
Next Article Key Points “Medical Journeys” is a set of clinical resources reviewed by physicians, meant for the medical team as well as the patients they serve. Each episode of this journey through a disease state contains both a physician guide and a downloadable/printable patient resource. “Medical Journeys” chart a path each step of the […]
Rami Komrokji, MD Vice chair, Malignant Hematology Department Head of the Leukemia and MDS Section Moffitt Cancer Center Tampa, FL KOMROKJI: MF could be either primary de novo or coming from secondary from essential thrombocythemia [ET] or polycythemia vera [PT]. [Concerning] the major criteria listed [by the World Health Organization (WHO)], I always bring up […]
Marisol Miranda-Galvis, DDS, MS, PhD Findings from a systematic review of several observational studies reveal that increasing disparities in survival outcomes within hematologic malignancies can be primarily attributed to 5 social determinants of health: lack of access to health insurance, treatment at a non-academic facility, low income or education level, and unmarried status. Key takeaways […]
Blood cells © Катерина Євтехова – stock.adobe.com In hematologic cancers, not having health insurance, being treated at a non-academic facility, having a low income or education level, and being unmarried, contribute to inequities in the outcomes for patients, according to findings from a systematic review. Key takeaways from the review were presented at the 2023 […]
Bayside, NY September 07, 2023 –(PR.com)– New York Cancer & Blood Specialists (NYCBS), one of the nation’s leading oncology practices, is proud to announce the addition of oncologist-hematologist Jean Bustamante-Alvarez, MD, MS. Dr. Bustamante-Alvarez will be joining the team in the Upper East Side at 215 E. 95th St., New York, NY 10128. “We are […]